Gabexate Mesilate for Injection
Time: 2022-02-12
Gabexate Mesilate for Injection | |
| 1. Dosage forms and specifications | Injection 100mg,500mg |
| 2. Indications | For the treatment of acute mild (oedematous) pancreatitis and also as an adjunct to acute haemorrhagic necrotizing pancreatitis. |
| 3. Dosage | This product is for intravenous drip use only, 100mg per dose, 300mg per day for 3 days at the beginning of treatment, then 100mg/day for 6-10 days after the symptoms have subsided. Inject 5ml of water for injection into the lyophilised powder vial with this product, and after dissolution, transfer into 5% dextrose solution or Ringer’s solution 500ml for intravenous drip. The drip rate should not be too fast and should be limited to 1mg/kg/h and should not exceed 2.5mg/kg/h. |
| 4. Reference preparation | Trade name：FOY； Holder：丸石製薬株式会社/小野薬品工業株式会社 |
| 5. Marketing status | Domestic：14 lot numbers in China, all with a size of 0.1g; no imports； Foreign：marketed in Japan (1 original + 4 generic) |
| 6. API | Gabexate mesylate: 8 domestic companies have registered. |
| 7. Medical insurance | Medicare Category B |
| 8. Patents | None |
| 9. Registration filings | Recently, 2 supplementary applications |
| 10. Registration classification | Classified 3 of Chemicals |
| 11. Project advantages |
|
